BridgeBio is significantly advanced this course of a new treatment for cardiac amyloidosis, employing the investigational drug. Early patient data suggests promising improvements for patients affected with a severe https://attruby852286.ivasdesign.com/63295826/company-improves-attr-cm-therapy-with-the-drug